Risk of anaphylaxis associated with IV iron highest for iron dextran, lowest for iron sucrose.
Having hemoglobin 9-11 g/dL prior to dialysis provided the best life expectancy.
It is unclear whether RDW is a risk factor for early death or a byproduct of biological and metabolic imbalances.
Patients prescribed the lipid-lowering agents were less likely to exhibit hyporesponsiveness to the medications.
Study finds no gender differences in parathyroid hormone, ferritin, Kt/V, or age.
In a study, the mean hemoglobin level increased significantly in hemodialysis patients with functional iron deficiency.
The association is independent of anemia, according to researchers.
Patients with vs. without protein-energy wasting syndrome had a significantly lower mean hemoglobin level.
Hepatitis C viral infection found to increase likelihood of requiring blood transfusions and hemoglobin levels dropping below 8.5 g/dL.
Iron deficiency may contribute to the relationship between proteinuria and excess FGF-23, researchers suggested.
The odds of major adverse cardiac events were 46% to 76% higher in anemic vs. non-anemic patients.
Unlike serum ferritin, transferrin saturation demonstrated an ability to predict the need for intravenous iron and ESA.
RED-HF study confirms the increased stroke risk observed in TREAT.
Successfully treating anemia in pre-dialysis CKD patients appears to prevent left ventricular remodeling.
Kidney disease patients with macroalbuminuria were 86% more likely to be anemic.
Trial stopped early due to a higher risk of serious cardiovascular events and infections with IV iron versus oral iron.
It was associated with a 15% reduced risk of early death among pre-dialysis, stage 5 chronic kidney patients treated with ESAs.
It reduces dose requirements and lowers the risk of death and hospitalization for cardiovascular complications compared with IV administration.
Researchers find link in the non-dialysis population.
Proteinuria, hyperphosphatemia, anemia linked more rapid annual decline in eGFR.
The Food and Drug Administration (FDA) has strengthened an existing warning regarding serious and potentially fatal allergic reactions that can occur with Feraheme (ferumoxytol; AMAG Pharmaceuticals).
The medication may represent a new treatment option for dialysis patients, researchers concluded.
Soluble ferric pyrophosphate is given to hemodialysis patients via dialysate.
Levels below 10 g/dL found to increase risk of a composite endpoint of all-cause mortality, cerebrovascular events, and myocardial infarction.
Over 52 weeks, the drug maintained hemoglobin levels while decreasing IV iron use in dialysis patients with anemia.
Benefit seen among anemia and hemodialysis patients with hemoglobin levels below 10 g/dL.
Renal events are significantly less likely if erythropoiesis-stimulating agents are started at hemoglobin levels below 11 g/dL.
New finding on vitamin B6 is the opposite of what investigators hypothesized on patients with anemia.
IV iron in anemia hemodialysis patients hospitalized for bacterial infections found not to worsen outcomes.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)